Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma
- PMID: 7866277
- DOI: 10.3109/10428199409049726
Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma
Abstract
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79%) achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39%). CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (AraC), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49%) remain in CR with a followup to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).
Similar articles
-
Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.Jpn J Clin Oncol. 1999 Jul;29(7):340-8. doi: 10.1093/jjco/29.7.340. Jpn J Clin Oncol. 1999. PMID: 10470659 Clinical Trial.
-
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.Blood. 1995 Apr 15;85(8):2025-37. Blood. 1995. PMID: 7718875 Clinical Trial.
-
[Therapeutic management of central nervous system lymphomas in a single hematological institute].Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Orv Hetil. 2009. PMID: 19812012 Hungarian.
-
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review.
-
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.J Clin Oncol. 2001 Oct 15;19(20):4014-22. doi: 10.1200/JCO.2001.19.20.4014. J Clin Oncol. 2001. PMID: 11600602 Review.
Cited by
-
Lymphoblastic lymphoma in adults.Curr Hematol Malig Rep. 2006 Dec;1(4):241-7. doi: 10.1007/s11899-006-0005-8. Curr Hematol Malig Rep. 2006. PMID: 20425319 Review.
-
Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients.Oncotarget. 2017 Jul 26;8(58):99104-99111. doi: 10.18632/oncotarget.19572. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228756 Free PMC article.
-
Over-expressed Fas improves the apoptosis of malignant T-cells in vitro and vivo.Mol Biol Rep. 2011 Nov;38(8):5371-7. doi: 10.1007/s11033-011-0689-2. Epub 2011 Mar 11. Mol Biol Rep. 2011. PMID: 21390503
-
A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma.Oncotarget. 2016 Jun 21;7(25):38884-38891. doi: 10.18632/oncotarget.9144. Oncotarget. 2016. PMID: 27150061 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
